Effect of adjunct Vitamin D treatment in vitamin D deficient pulmonary tuberculosis patients: A randomized, double blind, active controlled clinical trial

Q3 Medicine
Harish Chandra , Adil Rahman , Prashant Yadav , Geeta Maurya , Sushil Kumar Shukla
{"title":"Effect of adjunct Vitamin D treatment in vitamin D deficient pulmonary tuberculosis patients: A randomized, double blind, active controlled clinical trial","authors":"Harish Chandra ,&nbsp;Adil Rahman ,&nbsp;Prashant Yadav ,&nbsp;Geeta Maurya ,&nbsp;Sushil Kumar Shukla","doi":"10.1016/j.ijtb.2023.04.026","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p><span>Since, Vitamin D [1α,25(OH)</span><sub>2</sub><span>D)] enhances antimicrobial activity of Innate immunity and modulate Adaptive immune responses, simultaneously, so it play a potential role for balanced immune activity against </span><span><em>Mycobacterium tuberculosis</em></span><span><span> and restricting tissue injuries within the TB patients.(Chun et al., 2011) 9 We aimed to determine the role of adjunct Vitamin D treatment on the outcome of </span>pulmonary tuberculosis<span> patients and evaluated the effect of Vitamin D administration on Differential Leucocyte Count, Erythrocyte Sedimentation Rate<span><span>, serum Adenosine deaminase, serum C- reactive protein, </span>Oxygen saturation (SpO2) and Body Weight in Vitamin D deficient pulmonary tuberculosis patients.</span></span></span></p></div><div><h3>Methods</h3><p><span><span>We conducted a prospective, interventional, randomized, double blind, parallel group, active controlled clinical trial. Newly diagnosed Vitamin D deficient pulmonary tuberculosis patients were randomly assigned to intervention group (received standard anti-tubercular treatment with adjunct Vitamin D3) and control group (received standard anti-tubercular treatment without adjunct Vitamin D3). Total four doses [each dose of 2.5 mg (100000 IU)] of </span>Vitamin D3 were given, orally. First dose was given within 7 days of starting anti-tubercular treatment and second, third, fourth dose were given at 2, 4 and 6 weeks respectively. At the time of enrollment, we measured all baseline characteristics. During follow-up, we measured the study variables and monitored adverse events at 2, 4, 6, 8 and 12 weeks. Our safety parameter was serum corrected calcium level to assess the risk of </span>hypercalcemia.</p></div><div><h3>Results</h3><p>Total 130 pulmonary TB patients, 65 patients in each group, were analyzed. Our study results showed that decrease in Neutrophil count was statistically significant with small effect sizes at every time point of measurement and increase in Lymphocyte count was statistically significant with small and moderate effect sizes at 4, 6 and 8 week for intervention group than for control group. Decrease in erythrocyte sedimentation rate was statistically significant with small effect sizes at 6 and 8 week, decrease in serum adenosine deaminase and serum C- reactive protein was statistically significant with moderate effect sizes at 4, 6 and 8 week for intervention group than for control group. Increase in Oxygen saturation was statistically significant at 4 week with small effect size and increase in body weight was statistically significant with small effect sizes for intervention group than for control group. No case of hypercalcemia was reported.</p></div><div><h3>Conclusion</h3><p>Our findings suggest a potential role of adjunctive Vitamin D3 to accelerate resolution of inflammatory responses and improvement in clinical outcomes of pulmonary TB patients.</p></div><div><h3>Trial registration</h3><p><span>This trial is registered with Clinical Trials Registry - INDIA (</span><span>http://ctri.nic.in</span><svg><path></path></svg>) with CTRI Number - CTRI/2021/11/037914.</p></div><div><h3>Place of study</h3><p>Room Number 27, first floor out-patients department (OPD) and inpatient Wards, fourth floor, Department of Respiratory Medicine, Uttar Pradesh University of Medical Sciences, Saifai, Etawah (U.P.), INDIA.</p></div>","PeriodicalId":39346,"journal":{"name":"Indian Journal of Tuberculosis","volume":"71 2","pages":"Pages 170-178"},"PeriodicalIF":0.0000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Journal of Tuberculosis","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0019570723000835","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Since, Vitamin D [1α,25(OH)2D)] enhances antimicrobial activity of Innate immunity and modulate Adaptive immune responses, simultaneously, so it play a potential role for balanced immune activity against Mycobacterium tuberculosis and restricting tissue injuries within the TB patients.(Chun et al., 2011) 9 We aimed to determine the role of adjunct Vitamin D treatment on the outcome of pulmonary tuberculosis patients and evaluated the effect of Vitamin D administration on Differential Leucocyte Count, Erythrocyte Sedimentation Rate, serum Adenosine deaminase, serum C- reactive protein, Oxygen saturation (SpO2) and Body Weight in Vitamin D deficient pulmonary tuberculosis patients.

Methods

We conducted a prospective, interventional, randomized, double blind, parallel group, active controlled clinical trial. Newly diagnosed Vitamin D deficient pulmonary tuberculosis patients were randomly assigned to intervention group (received standard anti-tubercular treatment with adjunct Vitamin D3) and control group (received standard anti-tubercular treatment without adjunct Vitamin D3). Total four doses [each dose of 2.5 mg (100000 IU)] of Vitamin D3 were given, orally. First dose was given within 7 days of starting anti-tubercular treatment and second, third, fourth dose were given at 2, 4 and 6 weeks respectively. At the time of enrollment, we measured all baseline characteristics. During follow-up, we measured the study variables and monitored adverse events at 2, 4, 6, 8 and 12 weeks. Our safety parameter was serum corrected calcium level to assess the risk of hypercalcemia.

Results

Total 130 pulmonary TB patients, 65 patients in each group, were analyzed. Our study results showed that decrease in Neutrophil count was statistically significant with small effect sizes at every time point of measurement and increase in Lymphocyte count was statistically significant with small and moderate effect sizes at 4, 6 and 8 week for intervention group than for control group. Decrease in erythrocyte sedimentation rate was statistically significant with small effect sizes at 6 and 8 week, decrease in serum adenosine deaminase and serum C- reactive protein was statistically significant with moderate effect sizes at 4, 6 and 8 week for intervention group than for control group. Increase in Oxygen saturation was statistically significant at 4 week with small effect size and increase in body weight was statistically significant with small effect sizes for intervention group than for control group. No case of hypercalcemia was reported.

Conclusion

Our findings suggest a potential role of adjunctive Vitamin D3 to accelerate resolution of inflammatory responses and improvement in clinical outcomes of pulmonary TB patients.

Trial registration

This trial is registered with Clinical Trials Registry - INDIA (http://ctri.nic.in) with CTRI Number - CTRI/2021/11/037914.

Place of study

Room Number 27, first floor out-patients department (OPD) and inpatient Wards, fourth floor, Department of Respiratory Medicine, Uttar Pradesh University of Medical Sciences, Saifai, Etawah (U.P.), INDIA.

维生素D辅助治疗维生素D缺乏型肺结核患者的疗效:一项随机、双盲、主动对照的临床试验
背景由于维生素 D [1α,25(OH)2D)]能同时增强先天性免疫的抗菌活性和调节适应性免疫反应,因此它在平衡结核分枝杆菌的免疫活性和限制结核病患者的组织损伤方面发挥着潜在的作用、9 我们旨在确定维生素 D 辅助治疗对肺结核患者预后的作用,并评估维生素 D 给药对维生素 D 缺乏性肺结核患者的白细胞计数差异、红细胞沉降率、血清腺苷脱氨酶、血清 C 反应蛋白、血氧饱和度(SpO2)和体重的影响。新确诊的维生素 D 缺乏性肺结核患者被随机分配到干预组(接受标准抗结核治疗,同时辅助维生素 D3)和对照组(接受标准抗结核治疗,同时不辅助维生素 D3)。干预组共口服四剂维生素 D3(每剂 2.5 毫克(100000 IU))。第一剂在开始抗结核治疗后 7 天内服用,第二、三、四剂分别在 2、4 和 6 周后服用。入组时,我们测量了所有基线特征。在随访期间,我们分别在 2、4、6、8 和 12 周测量了研究变量并监测了不良事件。我们的安全参数是血清校正钙水平,以评估高钙血症的风险。研究结果表明,与对照组相比,干预组的中性粒细胞计数在每个测量时间点的下降都具有统计学意义,影响程度较小;淋巴细胞计数在第 4、6 和 8 周的上升都具有统计学意义,影响程度为小和中等。干预组的红细胞沉降率在 6 周和 8 周时的下降具有统计学意义,影响程度较小;干预组的血清腺苷脱氨酶和血清 C 反应蛋白在 4 周、6 周和 8 周时的下降具有统计学意义,影响程度中等。干预组与对照组相比,氧饱和度在 4 周时的增加具有统计学意义,但影响程度较小;干预组与对照组相比,体重的增加具有统计学意义,但影响程度较小。没有高钙血症病例的报告。结论我们的研究结果表明,辅助维生素 D3 有可能加速肺结核患者炎症反应的缓解并改善其临床疗效。试验注册本试验已在印度临床试验注册中心注册(http://ctri.nic.in)注册,CTRI编号为- CTRI/2021/11/037914。研究地点印度北方邦埃塔瓦(U.P.)塞法伊市北方邦医科大学呼吸内科一楼门诊部(OPD)和四楼住院病房27号房间。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Indian Journal of Tuberculosis
Indian Journal of Tuberculosis Medicine-Infectious Diseases
CiteScore
2.80
自引率
0.00%
发文量
103
期刊介绍: Indian Journal of Tuberculosis (IJTB) is an international peer-reviewed journal devoted to the specialty of tuberculosis and lung diseases and is published quarterly. IJTB publishes research on clinical, epidemiological, public health and social aspects of tuberculosis. The journal accepts original research articles, viewpoints, review articles, success stories, interesting case series and case reports on patients suffering from pulmonary, extra-pulmonary tuberculosis as well as other respiratory diseases, Radiology Forum, Short Communications, Book Reviews, abstracts, letters to the editor, editorials on topics of current interest etc. The articles published in IJTB are a key source of information on research in tuberculosis. The journal is indexed in Medline
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信